Prostate cancer (PCa) is the second most common type of cancer worldwide, and the fifth leading cause of cancer death. New detection strategies have increased incidence rates in the last twenty years, and innovative therapeutic and risk-assessed strategies have drastically improved the 5-year survival expectancy of patients. Advanced prostate cancer, however, caused by the metastasization of aberrant cancer cells, is invariably fatal. This is thanks to the adaptive survival strategies of the tumor itself, which can become resistant to standard androgen-deprivation techniques and chemotherapeutic drugs. Prostate cancer undergoes two radical changes before becoming metastatic: one is the Epithelial-to-Mesenchymal Transition (EMT), which is the main hallmark of the start of the invasion of distant tissues and organs; the other is a change in the metabolism of the cancer cells themselves, which start relying on the beta oxidation of fatty acids instead of consumption of glucose for their metabolic needs.